What a Methadone–Buprenorphine Trial Can Establish About Stimulant Co-Use

A comparison of opioid treatments can examine stimulant co-use without showing that either treatment is an established methamphetamine intervention. A Canadian analysis illustrates why the comparison and its confidence interval matter.

The study compared models of care

Langlois and colleagues analyzed a 24-week pragmatic trial comparing supervised methadone with flexible take-home buprenorphine/naloxone care. The analysis included 210 participants who initiated opioid agonist therapy; 130 had methamphetamine/amphetamine use at baseline.

Use was assessed with urine testing and self-report. The study’s combined methamphetamine/amphetamine category should not be silently relabeled as an exclusively methamphetamine-specific endpoint.

No clear treatment difference was established

The adjusted treatment comparison yielded an odds ratio of 0.61 with a 95% confidence interval of 0.34–1.08. The interval included the no-difference value of 1. The time-in-treatment comparison and treatment-by-time interaction also were not statistically significant.

A point estimate below 1 can motivate further investigation. It does not establish superiority when the uncertainty includes no difference, and a nonsignificant finding does not establish exact equivalence.

Preserve the actual treatment context

The comparison involved medication and delivery arrangements. It should not be treated as a laboratory experiment that isolates a single pharmacological effect from every feature of supervised versus take-home care.

These results concern people initiating care for opioid use disorder. They neither justify withdrawing opioid treatment because of stimulant use nor determine the expected course of an individual patient.

Scientific source

Langlois J and colleagues. Comparative Effectiveness of Buprenorphine/Naloxone and Methadone on Methamphetamine/Amphetamine Use Among People with Opioid Use Disorder in Canada. Substance Use & Addiction Journal. 2025;46:518–530. doi:10.1177/29767342241298044. Based on the supplied trial analysis.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Why Trace Opioid Detection Is Different From a Verified Adulterated Dose

Short answer: Detecting an unexpected opioid at trace level does not, by itself, establish that a product contained an active adulterating dose. In a British Columbia drug-checking study, 189 of 8,889 samples not expected to include fentanyl had an unexpected opioid, and 61.4% of those detections were at trace concentration….

Spread the love

Read Article: Why Trace Opioid Detection Is Different From a Verified Adulterated Dose

Were Nitazenes Present in Most Ontario Opioid Deaths? Read the 79-of-8,719 Denominator

Short answer: No. In coroner data analyzed for a Canadian study, nitazenes were present in 79 of 8,719 Ontario opioid deaths (0.91%) from January 2019 through December 2022. The Toronto subset was 33 of 1,803 opioid deaths (1.83%). These are presence counts in specified death records, not evidence that nitazenes…

Spread the love

Read Article: Were Nitazenes Present in Most Ontario Opioid Deaths? Read the 79-of-8,719 Denominator

Why a GHB Result May Not Identify the Substance Originally Taken

Short answer: A test that reports GHB does not necessarily identify the substance a person originally took. A scientific review by Busardò and Jones explains that gamma-butyrolactone (GBL) and 1,4-butanediol can convert rapidly to GHB after ingestion. The measured GHB is a real analytical finding, but the starting compound is…

Spread the love

Read Article: Why a GHB Result May Not Identify the Substance Originally Taken

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us